None of the participants who got durvalumab and olaparib died because of
serious adverse reactions during the study.
There were 1.3% of participants who got durvalumab and the placebo who
died because of serious adverse reactions during the study. This was 1 out of 76
participants. The serious adverse reaction was having low levels of red blood cells,
also called anemia.
What adverse reactions happened during this study?
The most common adverse reaction was having low levels of red blood cells, also
called anemia.
The table below shows the adverse reactions that happened in 5.0% or more of
participants in either treatment group during the study. There were other adverse
reactions, but these happened in fewer participants.
Most common adverse reactions
Durvalumab and olaparib Durvalumab and placebo
Adverse reaction (out of 76 participants) (out of 76 participants)
Low levels of red blood cells, also 23.7% (18) 13.2% (10)
called anemia
Nausea 19.7% (15) 3.9% (3)
Diarrhea 10.5% (8) 2.6% (2)
Low appetite 10.5% (8) 2.6% (2)
Low levels of thyroid hormones 9.2% (7) 3.9% (3)
Itchiness 7.9% (6) 10.5% (8)
Rash 7.9% (6) 5.3% (4)
Dizziness 6.6% (5) 1.3% (1)
General weakness 5.3% (4) 1.3% (1)
10 | Clinical Study Results